Table I.
Transgenic Mice Rejected B7-1+ but Not B7-1− J558 Tumor Cells
| Mice | Tumors | Mice with tumors/ mice without tumors | ||
|---|---|---|---|---|
| TCR-TG+ | J558-B7 | 0/3 | ||
| J558-Neo | 5/9 | |||
| TCR-TG− | J558-B7 | 1/4 | ||
| J558-Neo | 4/8 | |||
| nu/nu | J558-B7 | 3/4 | ||
| J558-Neo | 3/4 |
N2 of BALB/cByJ × TCR−TG+ SW founder were screened for transgenic expression of the transgenic receptor by flow cytometry. Staining with PE–conjugated anti-Vα8 mAb revealed that ∼50% of PBL in the TG+ mice expressed the Vα8, whereas TG− mice have <2% of the Vα8+ T cells in the PBL. 6–12-wk-old mice were inoculated in the left inguen with 5 × 106 B7-1+ (J558-B7) or B7-1− (J558-Neo) tumor cells. Tumor incidences were determined by physical examination with a 2–3-d interval. Data presented are tumor incidences at 25–27 d after tumor cell inoculation.